The Community Oncology Alliance (COA) created its Payer Exchange Summit to get payers who are thinking about getting involved in oncology payment reform or want to know what to do exposed to successful pilots, explained Ted Okon, MBA, executive director of COA.
The Community Oncology Alliance (COA) created its Payer Exchange Summit to get payers who are thinking about getting involved in oncology payment reform or want to know what to do exposed to successful pilots, explained Ted Okon, MBA, executive director of COA.
Transcript (slightly modified for readability)
What is the objective of the Community Oncology Alliance's Payer Exchange Summit?
So at COA we had this dream over a year ago of getting providers and payers together at a summit. In fact, we called it the Payer Exchange Summit on Oncology Payment Reform. We wanted to get provider and payer teams that were actually working on oncology payment reform to talk about "what are we doing? What's working? What's not working?"
So now that we've done the first summit a year ago, we did the second summit when we devoted half a day at our conference in April, and now that we've just finished the third summit, we're really seeing a great opportunity here to get more payers involved in the dialogue. Not just the really progressive payers that are actually doing things in oncology payment reform, like Aetna, like UnitedHealthcare, but literally to get payers that are thinking about doing something or want to know what they should be doing to literally have them exposed to pilots that are working now with actual payers and providers.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More